Showing 1 - 20 results of 27 for search 'Keshu Zhou', query time: 0.07s Refine Results
  1. 1
    Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting

    Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting by Jingyi Yang, Hao Guo, Lu Han, Yongping Song, Keshu Zhou

    Published 2024-02-01
    Get full text
    Article
  2. 2
    Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms

    Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms by Hao Guo, Jingyi Yang, Haoran Wang, Xingchen Liu, Yanyan Liu, Keshu Zhou

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect

    Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect by Haoran Wang, Hao Guo, Jingyi Yang, Yanyan Liu, Xingchen Liu, Qing Zhang, Keshu Zhou

    Published 2022-09-01
    Get full text
    Article
  4. 4
    Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer

    Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer by Jing Ding, Deyu Li, Xingchen Liu, Hu Hei, Baoxi Sun, Dongmin Zhou, Keshu Zhou, Yongping Song

    Published 2022-09-01
    Get full text
    Article
  5. 5
    PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL

    PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL by Shenmiao Yang, Haiwen Huang, Keshu Zhou, Xielan Zhao, Yan-Qiu Han#, Lindong LI, Anna Butturini, Yiqiu Wang, Xiaofeng Liu, Peiqiong Lai, Jianyong LI

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

    Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cel... by Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian, Yuankai Shi

    Published 2024-12-01
    Get full text
    Article
  7. 7
    Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph+ B cell acute lymphoblastic leukemia

    Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph+ B cell acute lymphoblastic leukemia by Lu Han, Ran Zhao, Jingyi Yang, Yingling Zu, Yanyan Liu, Jian Zhou, Linlin Li, Zhenghua Huang, Jishuai Zhang, Quanli Gao, Yongping Song, Keshu Zhou

    Published 2022-09-01
    Get full text
    Article
  8. 8
    Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

    Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies by Lu Han, Jian Zhou, Linlin Li, Keshu Zhou, Lingdi Zhao, Xinghu Zhu, Qingsong Yin, Yufu Li, Hongqin You, Jishuai Zhang, Yongping Song, Quanli Gao

    Published 2021-11-01
    Get full text
    Article
  9. 9
    Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

    Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma by Zhen Li, Binglei Zhang, Xinxin Fan, Ruirui Gui, Fengkuan Yu, Juan Wang, Yanli Zhang, Keshu Zhou, Yanyan Liu, Yufu Li, Jing Ding, Yongping Song, Jian Zhou

    Published 2023-07-01
    Get full text
    Article
  10. 10
    Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus

    Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus by Jian Zhou, Lu Han, Keshu Zhou, Baijun Fang, Linlin Li, Quanli Gao, Hu Zhou, Yongping Song, Qingsong Yin, Xinghu Zhu, Lingdi Zhao, Xudong Wei, Bengling Xu, Jishuai Zhang

    Published 2020-10-01
    Get full text
    Article
  11. 11
    Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trialResearch in context

    Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or m... by Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang, Yongping Song, Jinjin Liang, Min Wei

    Published 2024-07-01
    Get full text
    Article
  12. 12
    P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

    P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA by Huilai Zhang, Ying Cheng, Hai-Yan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Zhiyu Liang, Jiaoyan Lyu, Yiqian Fang, Aileen Cohen, Keshu Zhou

    Published 2023-08-01
    Get full text
    Article
  13. 13
    P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MALIGNANCIES

    P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF BCL-2 INHIBITOR BGB-11417 IN ADULT PATIENTS WITH MATURE B-CELL MA... by Caixia LI, Jia Wei, Liu Peng, He Huang, Fei LI, Yujun Dong, Qingqing Cai, Shenmiao Yang, Xinyou Zhang, Hui Zhou, Lu Zhang, Zaixing Shi, Zhiyu Liang, Binghao Wu, Keshu Zhou, Depei Wu

    Published 2023-08-01
    Get full text
    Article
  14. 14
    A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy

    A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transpl... by Zhenghua Huang, Zhen Li, Juan Wang, Ruirui Gui, Yingling Zu, Fengkuan Yu, Quande Lin, Huifang Zhao, Yanli Zhang, Baijun Fang, Yanyan Liu, Keshu Zhou, Yufu Li, Yuewen Fu, Zhihua Yao, Yongping Song, Jian Zhou

    Published 2023-05-01
    Get full text
    Article
  15. 15
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study by Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng, Jianyong Li

    Published 2020-05-01
    Get full text
    Article
  16. 16
    P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION

    P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION by LI Wang, Yuhua LI, Dehui Zou, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang LI, Fei LI, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Wei-LI Zhao

    Published 2023-08-01
    Get full text
    Article
  17. 17
    Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

    Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis by Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu

    Published 2023-09-01
    Get full text
    Article
  18. 18
    Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

    Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials by Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang, Tycel J. Phillips, Stephen Opat, Zhiyue Huang, Huafei Lu, Yuqin Song, Yongping Song

    Published 2021-10-01
    Get full text
    Article
  19. 19
    P1167: TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB)，A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETING MYC DEGRADATION

    P1167: TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB)，A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETI... by Sung-Soo Yoon, Zhiming LI, Keshu Zhou, Xiaoxi Zhou, Ye Guo, Huilai Zhang, Ki-Seong Eom, Seok Jin Kim, Sung Yong Oh, Sungnam Lim, Hagop Youssoufian, Vernon C Jiang, Zanchun Huang, Georgina Kilfoil, Xin Wang, Zhixiang Cao, Xiang LI, Alexander Wu, Yiyou Chen, Yuqin Song

    Published 2023-08-01
    Get full text
    Article
  20. 20
    Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial

    Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial by Ningjing Lin, Xiuhua Sun, Hui Zhou, Liqun Zou, Keshu Zhou, Lihong Liu, Haiyan Yang, Kai Hu, Qingqing Cai, Yao Liu, Jie Jin, Liling Zhang, Wenyu Li, Ye Guo, Wei Yang, Feng Luo, Zhenguang Wang, Rong Zhu, Lei Yang, Dan Song, Yuqin Song, Jun Zhu

    Published 2024-09-01
    Get full text
    Article

Search Tools: